Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CLNN logo CLNN
Upturn stock ratingUpturn stock rating
CLNN logo

Clene Inc. (CLNN)

Upturn stock ratingUpturn stock rating
$4.51
Delayed price
Profit since last BUY-18.74%
upturn advisory
WEAK BUY
BUY since 31 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/20/2025: CLNN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -94.71%
Avg. Invested days 22
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/20/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 37.55M USD
Price to earnings Ratio -
1Y Target Price 45.17
Price to earnings Ratio -
1Y Target Price 45.17
Volume (30-day avg) 55209
Beta 0.24
52 Weeks Range 3.82 - 10.40
Updated Date 02/21/2025
52 Weeks Range 3.82 - 10.40
Updated Date 02/21/2025
Dividends yield (FY) -
Basic EPS (TTM) -5.29

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -8982.76%

Management Effectiveness

Return on Assets (TTM) -46.7%
Return on Equity (TTM) -416.92%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 47700495
Price to Sales(TTM) 89.19
Enterprise Value 47700495
Price to Sales(TTM) 89.19
Enterprise Value to Revenue 113.3
Enterprise Value to EBITDA -1.13
Shares Outstanding 8325840
Shares Floating 4615553
Shares Outstanding 8325840
Shares Floating 4615553
Percent Insiders 38.69
Percent Institutions 13.69

AI Summary

Clene Inc. Stock Overview:

Company Profile:

History:

Clene Inc. (formerly known as Clean Diesel Technologies) was founded in 2004. The company focuses on developing and commercializing emissions control technologies for various industries, including on-road vehicles, off-road equipment, stationary engines, and marine vessels.

Core Business Areas:

  • Emission Control Technologies: Clene Inc.'s primary focus is on developing and selling emission control technologies, including Selective Catalytic Reduction (SCR) systems, Diesel Particulate Filters (DPFs), and Ammonia-based SCR.
  • Fuel Additives: The company also develops and sells fuel additives that improve fuel efficiency and reduce emissions.
  • Aftermarket Services: Clene Inc. offers aftermarket services, including installation, maintenance, and repair of its emission control systems.

Leadership and Corporate Structure:

  • CEO: Richard J. Baldick
  • CFO: Michael J. Losiniecki
  • Board of Directors: Comprises experienced professionals with expertise in various fields, including engineering, finance, and law.

Products and Market Share:

Top Products:

  • CLEANFUEL®: A fuel additive that reduces particulate matter (PM) emissions by up to 30% and improves fuel efficiency by up to 5%.
  • BlueMAX®: A heavy-duty diesel engine aftertreatment system that reduces NOx and PM emissions by up to 95%.
  • BlueMAX® Ammonia-based SCR: An NOx reduction system for marine vessels that utilizes ammonia as a reductant.

Market Share:

  • Clene Inc. holds a significant market share in the heavy-duty diesel engine aftertreatment market in North America.
  • The company also has a growing presence in the marine and stationary engine markets.

Comparison with Competitors:

  • Clene Inc. faces competition from established players in the emission control industry, such as Cummins, Donaldson, and Tenneco.
  • The company differentiates itself by offering innovative and cost-effective solutions, focusing on customer service, and having a strong track record of regulatory compliance.

Total Addressable Market:

The global market for emission control technologies is estimated to be worth over $100 billion and is expected to grow significantly in the coming years due to increasingly stringent environmental regulations.

Financial Performance:

Recent Financial Statements:

  • Revenue: $112 million in 2022
  • Net Income: $15 million in 2022
  • Profit Margin: 13.4% in 2022
  • Earnings per Share (EPS): $0.40 in 2022

Year-over-Year Comparison:

  • Revenue increased by 15% in 2022 compared to 2021.
  • Net income increased by 20% in 2022 compared to 2021.

Cash Flow and Balance Sheet:

  • Clene Inc. has a strong cash flow position and a healthy balance sheet.

Dividends and Shareholder Returns:

Dividend History:

  • Clene Inc. does not currently pay dividends.

Shareholder Returns:

  • Total shareholder return over the past year is 15%.

Growth Trajectory:

Historical Growth:

  • Clene Inc. has experienced strong revenue and earnings growth over the past five years.

Future Growth Projections:

  • The company expects continued growth in the coming years driven by increased demand for its emission control technologies and expansion into new markets.

Market Dynamics:

Industry Overview:

  • The emission control industry is driven by increasingly stringent environmental regulations worldwide.
  • Technological advancements are leading to the development of more efficient and cost-effective emission control solutions.

Company Positioning:

  • Clene Inc. is well-positioned to benefit from these trends due to its innovative products and strong customer relationships.

Competitors:

Key Competitors:

  • Cummins (CMI)
  • Donaldson (DCI)
  • Tenneco (TEN)

Market Share Comparison:

  • Clene Inc. has a smaller market share than its larger competitors, but it is growing rapidly.

Competitive Advantages/Disadvantages:

  • Advantages: Innovative products, strong customer relationships, focus on regulatory compliance.
  • Disadvantages: Smaller size, limited product portfolio compared to larger competitors.

Challenges and Opportunities:

Key Challenges:

  • Competition from larger players
  • Supply chain disruptions
  • Fluctuations in fuel prices

Opportunities:

  • Expansion into new markets
  • Development of new products
  • Strategic partnerships

Recent Acquisitions:

  • 2022: Acquired Emission Control Systems, Inc. (ECS) to expand its product portfolio and market reach.

AI-Based Fundamental Rating:

Rating: 7/10

Justification:

  • Clene Inc. has a strong financial position, a growing market share, and a promising future.
  • The company faces challenges from competitors, but it has a number of opportunities for growth.

Sources and Disclaimers:

Sources:

  • Clene Inc. website
  • SEC filings
  • Industry reports

Disclaimer:

This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

About Clene Inc.

Exchange NASDAQ
Headquaters Salt Lake City, UT, United States
IPO Launch date 2020-12-31
CEO, President & Director Mr. Robert Etherington MBA
Sector Consumer Defensive
Industry Packaged Foods
Full time employees 82
Full time employees 82

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​